Papers
1
Total Citations
173
H-Index
1
About
Dr. P.S. Doyle is a leading figure in antiparasitic drug discovery, with a particular focus on neglected tropical diseases. Her research centers on developing new therapeutics for Chagas disease, a life-threatening illness caused by the protozoan parasite *Trypanosoma cruzi*. A key contribution is her pioneering work in target-based drug discovery, notably identifying and validating the parasite’s cytochrome P450 enzyme as a critical drug target. Her highly cited 2009 review, with 173 citations, remains a seminal resource, outlining the dual strategies of target-based and phenotypic screening used at the Sandler Center, UCSF. This work has directly influenced the development of leading clinical candidates, including the ergosterol biosynthesis inhibitor posaconazole. Dr. Doyle’s impact is measured not only in citations but in her role advancing the global pipeline for Chagas disease treatments, bridging fundamental parasitology with translational medicine to address a devastating public health challenge.
Research Focus
Key Achievements
Top Papers
- 1Two approaches to discovering and developing new drugs for Chagas disease173 citations · 2009